Post-trial follow-up | Long-term treatment with Ponesimod in relapsing-remitting multiple sclerosis.

Long-term Treatment With Ponesimod in Relapsing-Remitting Multiple Sclerosis: Results From Randomized Phase 2b Core and Extension Studies – Neurology

Commentary: Optimal Dose of Ponesimod for Control of Relapsing-Remitting Multiple Sclerosis – Neurology Advisor

Original Study: Oral ponesimod in relapsing–remitting multiple sclerosis: a randomised phase II trial – Journal of Neurology, Neurosurgery & Psychiatry